History, biology, and health inequities: Emergent embodied phenotypes and the illustrative case of the breast cancer estrogen receptor

American Journal of Public Health

Volumn 103, Issue 1, 2013, Pages 22-27

  Krieger, Nancy ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ARTICLE; BREAST TUMOR; DEVELOPMENTAL BIOLOGY; FEMALE; HEALTH CARE DISPARITY; HUMAN; INDIVIDUALITY; METABOLISM; MORTALITY; PHENOTYPE; SOCIAL CLASS;

BREAST NEOPLASMS; DEVELOPMENTAL BIOLOGY; FEMALE; HEALTHCARE DISPARITIES; HUMANS; INDIVIDUALITY; PHENOTYPE; RECEPTORS, ESTROGEN; SOCIAL CLASS;

EID: 84872592609     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2012.300967     Document Type: Review

References (79)

1. Gilbert SF, Epel D. Ecological Developmental Biology: Integrating Epigenetics, Medicine, and Evolution. Sunderland, MA: Sinaeur Associates; 2009.
2. West-Eberhard MT. Developmental Plasticity and Evolution. New York, NY: Oxford University Press; 2003.
3. Lewontin R. The Triple Helix: Gene, Organism, and Environment. Cambridge, MA: Harvard University Press; 2000.
4. Keller EF. The Mirage of a Space Between Nature and Nurture. Durham, NC: Duke University Press; 2010.
5. Krieger N. Epidemiology and The People's Health: Theory and Context. New York, NY: Oxford University Press; 2011.
6. National Institutes of Health. Biennial Report of the Director, Fiscal Years 2008 & 2009. Available at: http://report. nih.gov/biennialreport. Accessed May 6, 2012.
7. Kaiser J. NIH director bends budget to fit five themes. ScienceInsider, February 1, 2010. Available at: http://news. sciencemag.org/scienceinsider/2010/ 02/nih-director-be.html. Accessed May 7, 2012.
8. Dobzhansky T. Nothing in biology makes sense except in the light of evolution. Am Biol Teach. 1973;35:125-129.
9. Piermsa T, van Gils JA. The Flexible Phenotype: A Body-Centered Integration of Ecology, Physiology, and Behavior. New York, NY: Oxford University Press; 2011.
10. Carroll SB. Endless Forms Most Beautiful: The New Science of Evo-Devo. New York, NY: W. W. Norton; 2005.
11. Davey Smith G. Epigenesis for epidemiologists: does evo-devo have implications for population health research and practice? Int J Epidemiol. 2012;41(1): 236-247.
12. Bateson P, Gluckman P. Plasticity and robustness in development and evolution. Int J Epidemiol. 2012;41(1): 219-223.
13. Kuzawa C. Why evolution needs development, and medicine needs evolution. Int J Epidemiol. 2012;41(1):223-229.
14. McMichael A. Human Frontiers, Environments, and Disease: Past Patterns, Uncertain Futures. Cambridge, UK: Cambridge University Press; 2001.
15. Godwin J. Neuroendocrinology of sexual plasticity in teleost fishes. Front Neuroendocrinol. 2010;31(2):203-216.
16. Krieger N, Chen JT, Coull BA, Selby JV. Lifetime socioeconomic position and twins" health: an analysis of 308 pairs of United States women twins. PLoS Med. 2005;2(7):e162.
17. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 2004;13(10): 1558-1568. (Pubitemid 39331875)
18. Rodenhiser DI, Andrews JD, Vandenberg TA, Chambers AF. Gene signatures of breast cancer progression and metastasis. Breast Cancer Res. 2011; 13(1):201.
19. Lopez-Tarruella S, Schiff R. The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm. Clin Cancer Res. 2007;13(23):6921-6925. (Pubitemid 350276870)
20. Heldring N, Pike A, Andersson S, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 2007;87(3):905-931. (Pubitemid 47084672)
21. McLachlan JA. Environmental signaling: what embryos and evolution teach us about endocrine disrupting chemicals. Endocr Rev. 2001;22(3): 319-341. (Pubitemid 32554362)
22. Sladek FM. What are nuclear receptor ligands? Mol Cell Endocrinol. 2011;334(1-2):3-13.
23. Krieger N. Theories for social epidemiology in the 21st century: an ecosocial perspective. Int J Epidemiol. 2001;30 (4):668-677. (Pubitemid 32827362)
24. Krieger N. Epidemiology and the web of causation: has anyone seen the spider? Soc Sci Med. 1994;39(7): 887-903. (Pubitemid 24264502)
25. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to estrogen and progesterone receptor status: a meta-analysis of epidemiologic studies. Breast Cancer Res. 2006;8(4):R43.
26. Wallace TA, Martin DN, Ambs S. Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis. 2011;32(8):1107-1121.
27. Dunn BK, Agurs-Collins T, Browne D, Lubet R, Johnson KA. Health disparities in breast cancer: biology meets socioeconomic status. Breast Cancer Res Treat. 2010;121(2): 281-292.
28. Vona-Davis L, Rose DP. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health (Larchmt). 2009;18(6):883-893.
29. ErnstW, Harris B, eds. Race, Science, and Medicine, 1700-1960. London, UK: Routledge; 1999.
30. Winant H. Race and race theory. Annu Rev Sociol. 2000;26:169-185.
31. Risch N. Dissecting racial and ethnic difference. N Engl J Med. 2006;354(4): 408-411.
32. Bustamante CD, Burchard EG, De la Vega FM. Genomics for the world. Nature. 2011;475(7355):163-165.
33. Koenig BA, Lee S-J, Richardson SS, eds. Revisiting Race in a Genomic Age. New Brunswick, NJ: Rutgers University Press; 2008.
34. Whitmarsh I, Jones D, eds. What's the Use of Race? Modern Governance and the Biology of Difference. Cambridge, MA: MIT Press; 2010.
35. Weiss KM, Long JC. Non-Darwinian estimation: my ancestors, my genes" ancestors. Genome Res. 2009;19(5):703-710.
36. Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378(9801):1461-1484.
37. Ferlay J, Forman D, Mathers CD, Bray F. Lancet. 2012;379(9824):1390-1391.
38. Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378(9801): 1461-1484.
39. Krieger N, Bassett MT, Gomez SL. Lancet. 2012;379(9824):1391-1392.
40. Comment on: Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378(9801): 1461-1484.
41. Morris JN. Uses of Epidemiology. Edinburgh, UK: E. & S. Livingston; 1957.
42. Kunitz SJ. The Health of Populations: General Theories and Particular Realities. New York, NY: Oxford University Press; 2006.
43. Davey Smith G, ed. Health Inequalities: Lifecourse Approaches. Bristol, UK: University of Bristol Policy Press; 2003.
44. Chan L, O'Malley BW. Mechanism of the action of the sex steroid hormones (first of three parts). N Engl J Med. 1976; 294(24):1322-1328.
45. McGuire WL. Current status of estrogen receptors in human breast cancer. Cancer. 1975;36(2):638-644.
46. O'Malley BW, Means AR. Female steroid hormones and target cell nuclei. Science. 1974;183(4125): 610-620.
47. Aronowitz RA. Unnatural History: Breast Cancer and American Society. Cambridge, UK: Cambridge University Press; 2007.
48. Fletcher SW. Breast cancer screening: a 35 year perspective. Epidemiol Rev. 2011;33(1):165-175.
49. Krieger N, Löwy I, Aronowitz R, et al. Hormone replacement therapy, cancer, controversies and women's health: historical, epidemiological, biological, clinical and advocacy perspectives. J Epidemiol Community Health. 2005;59 (9):740-748.
50. Krieger N. Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections. Int J Epidemiol. 2008;37(3):627-637. (Pubitemid 351804018)
51. Watkins ES. The Estrogen Elixir: A History of Hormone Replacement Therapy in America. Baltimore, MD: Johns Hopkins University Press; 2007.
52. Feinleib M, Garrison RJ. Interpretation of the vital statistics of breast cancer. Cancer. 1969;24(6):1109-1116.
53. Logan WPD. Cancer Mortality by Occupation and Social Class: 1851-1971. London, UK: Her Majesty's Stationary Office; 1982. Studies on Medical and Population Subjects No. 44.
54. Krause S, Oppenheim A. Trend of mortality from cancer of the breast. JAMA. 1965;194:89-90.
55. Parkin DM, Sitas F, Chirenje M, et al. Cancer in Indigenous Africans-burden, distributions, and trends. Lancet Oncol. 2008;9(7):683-692. (Pubitemid 351878054)
56. Gibson C, Jung K. Historical Census Statistics on Population Totals by Race, 1790 to 1990, and by Hispanic Origin, 1970 to 1990, for the United States, Regions, Divisions, and States. Washington, DC: US Census Bureau; 2002. US Census Bureau Working Paper Series No. 56. Available at: http://www.census.gov/ population/www/documentation/twps0056/twps0056.html. Accessed May 7, 2012.
57. Krieger N, Chen JT, Waterman PD. Temporal trends in the black/white breast cancer case ratio for estrogen receptor status: disparities are historically contingent, not innate. Cancer Causes Control. 2011;22(3): 511-514.
58. Rossouw JE, Anderson GL, Prentice RL, et al. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3): 321-333. (Pubitemid 34761611)
59. Brett KM, Madans JH. Difference in use of postmenopausal hormone replacement therapy by black and white women. Menopause. 1997;4(2): 66-70. (Pubitemid 127729498)
60. Friedman-Koss D, Crespo CJ, Bellantoni MF, Andersen RE. The relationship of race/ethnicity and social class to hormone replacement therapy: results from the Third National Health and Nutrition Examination Survey 1988-1994. Menopause. 2002;9(4): 264-272. (Pubitemid 34743451)
61. Kuh DH, Ben-Shlomo Y, eds. A Lifecourse Approach to Chronic Disease Epidemiology. 2nd ed. Oxford, UK: Oxford University Press; 2004.
62. Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA. Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst. 2009;101(15):1058-1065.
63. Lindström LS, Karlsson E, Wilking UM, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable through tumor progression. J Clin Oncol. 2012;30(21):2601-2608.
64. Mavaddat N, Barrowdale D, Andrulis IL, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21(1): 134-147.
65. Ryle JA. The Natural History of Disease. Oxford, UK: Oxford University Press; 1936.
66. Anderson W. Natural histories of infectious disease: ecological vision in twentieth-century biomedical science. Osiris. 2004;19:39-61.
67. Ayres JR, Paiva V, França I Jr. From natural history of disease to vulnerability: changing concepts and practices in contemporary public health. In: Parker R, Sommer M, eds. Routledge Handbook of Global Public Health. New York, NY: Routledge; 2011:98-107.
68. Polyak K. Is breast tumor progression really linear? Clin Cancer Res. 2008; 14(2):339-341. (Pubitemid 351226097)
69. Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet. 2009; 25(1):30-38.
70. Polyak K, Kalluri R. The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol. 2010;2(11): a003244.
71. Foulds L. The experimental study of tumor progression: a review. Cancer Res. 1954;14(5):327-339.
72. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976; 194(4260):23-28.
73. Owen GI, Zelent A. Origins and evolutionary diversification of the nuclear receptor superfamily. Cell Mol Life Sci. 2000;57(5):809-827. (Pubitemid 30392037)
74. Sáez PJ, Lange S, Pérez-Acle T, Owen G. Nuclear receptor genes: evolution. In: Encyclopedia of Life Sciences. Available at: http://www.els.net/WileyDCA/ElsArticle/refid-a006145.html. Accessed September 14, 2012.
75. Baker ME, Chandsawangbhuwana C. Motif analysis of amphioxus, lamprey and invertebrate estrogen receptors: toward a better understanding of estrogen receptor evolution. Biochem Biophys Res Commun. 2008;371(4):724-728.
76. Baker ME. Origin and diversification of steroids: co-evolution of enzymes and nuclear receptors. Mol Cell Endocrinol. 2011;334(1-2):14-20.
77. Markov GV, Laudet V. Origin and evolution of the ligand-binding ability of nuclear receptors. Mol Cell Endocrinol. 2011;334(1-2): 21-30.
78. Eick GN, Thornton JW. Evolution of steroid receptors from an estrogen-sensitive ancestral receptor. Mol Cell Endocrinol. 2011;334(1-2): 31-38.
79. Asztalos S, Gann PH, Hayes MK, et al. Gene expression patterns in the human breast after pregnancy. Cancer Prev Res (Phila). 2010;3(3): 301-311.